Home

Shahzad Malik

CIK 1380178 · last filed 2021-06-22

Shahzad Malik is a corporate insider who has filed 30 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for AFIB, was dated Jun 22, 2021. Across all open-market trades the lifetime net is −$12.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $654.0K across reported positions. 7 SEC filings were submitted jointly with AGENUS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$654.0K

Companies

8

Total Filings

30

Lifetime Open-Market Net

-$12.43M

Filer Profile

Reported Address
2273 RESEARCH BLVD, SUITE 400
ROCKVILLE, MD 20850
Related Filers
AGENUS INC — 7 joint filings, latest 2016-06-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Acutus Medical, Inc. (AFIB) Delisted Director 69,458 $0.09 $6.3K $0 3 2021-06-22
Iterum Therapeutics plc (ITRM) Delisted Director 55,888 $0.03 $1.7K $3.08M 4 2020-01-23
Aravive, Inc. (ARAV) Delisted Director — $0.04 — $0 3 2019-09-13
Axonics, Inc. (AXNX) Delisted Director 60,734 $70.98 $4.31M $0 2 2018-12-10
Aravive, Inc. (VSAR) Delisted Director 274,240 — — -$9.73M 9 2017-12-22
Histogen Inc. (CNAT) Delisted Director 188,809 — — $2.08M 3 2016-06-27
AGEN Director 79,365 $8.24 $654.0K -$7.87M 5 2016-06-17
EBS Director — $6.21 — $0 1 2007-06-18

Recent Filings

30 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-06-22 Acutus Medical, Inc. (AFIB) Delisted Grant (A) +1,800 $0 EDGAR
2020-08-12 Acutus Medical, Inc. (AFIB) Delisted Conv (C) +1,617,149 $0 EDGAR
2020-08-07 Acutus Medical, Inc. (AFIB) Delisted Grant (A) +2,222 $0 EDGAR
2020-01-23 Iterum Therapeutics plc (ITRM) Delisted Grant (A) — $0 EDGAR
2019-09-13 Aravive, Inc. (ARAV) Delisted Grant (A) — $0 EDGAR
2019-06-17 Iterum Therapeutics plc (ITRM) Delisted Grant (A) — $0 EDGAR
2019-01-07 Aravive, Inc. (ARAV) Delisted Grant (A) — $0 EDGAR
2019-01-07 Aravive, Inc. (ARAV) Delisted Grant (A) — $0 EDGAR
2018-12-10 Axonics, Inc. (AXNX) Delisted Grant (A) +2,500 $0 EDGAR
2018-11-02 Axonics, Inc. (AXNX) Delisted Conv (C) +1,694,349 $0 EDGAR
Showing 1–10 of 30
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.